

**In the Abstract**

Amend the Abstract as follows:

The present invention provides ~~new~~ compounds of dinucleotide polyphosphates and the method of preventing or treating diseases or conditions associated with platelet aggregation. The method comprises administering systemically to a patient a pharmaceutical comprising a purinergic P2<sub>T</sub> receptor antagonist, in an amount effective to elevate its extracellular concentration to bind to P2<sub>T</sub> receptors and inhibit P2<sub>T</sub> receptor-mediated platelet aggregation. Methods of systemic administration include injection by intravenous, intramuscular, intrasternal and intravitreal routes, infusion, transdermal administration, oral administration, rectal administration and intra-operative instillation.